Travere Therapeutics (TVTX) Assets (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Assets came in at $555.2 million in Q1 2026, up 1.16% YoY from $548.8 million in Q1 2025, and down 8.26% on a QoQ basis from $605.2 million in Q4 2025.
Travere Therapeutics (TVTX) Assets (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Assets data on file, last reported at $555.2 million in Q1 2026.
- Quarterly Assets rose 1.16% year-over-year to $555.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $555.2 million (up 1.16% YoY) and the FY2025 annual result came in at $605.2 million, up 1.86% from the prior year.
- Assets fell to $555.2 million in Q1 2026, from $605.2 million in the prior quarter.
- In the past five years, Assets ranged from a high of $832.8 million in Q3 2023 to a low of $504.4 million in Q3 2024.
- A 5-year average of $664.1 million and a median of $663.5 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2023 — Assets advanced 17.3% — and 2024, when it sank 39.44%.
- Tracing TVTX's Assets over 5 years: stood at $672.6 million in 2022, then grew by 17.3% to $788.9 million in 2023, then fell by 24.69% to $594.1 million in 2024, then increased by 1.86% to $605.2 million in 2025, then dropped by 8.26% to $555.2 million in 2026.
- The last three Assets figures came in at $555.2 million (Q1 2026), $605.2 million (Q4 2025), and $538.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 799.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 799.36 Mn |
| Mar 31, 2026 | 555.19 Mn |
| Dec 31, 2025 | 605.19 Mn |
| Sep 30, 2025 | 538.58 Mn |
| Jun 30, 2025 | 555.31 Mn |
| Mar 31, 2025 | 548.80 Mn |
| Dec 31, 2024 | 594.13 Mn |
| Sep 30, 2024 | 504.41 Mn |
| Jun 30, 2024 | 551.12 Mn |
| Mar 31, 2024 | 663.55 Mn |
| Dec 31, 2023 | 788.91 Mn |
| Sep 30, 2023 | 832.85 Mn |
| Jun 30, 2023 | 736.43 Mn |
| Mar 31, 2023 | 808.23 Mn |
| Dec 31, 2022 | 672.59 Mn |
| Sep 30, 2022 | 726.22 Mn |
| Jun 30, 2022 | 779.49 Mn |
| Mar 31, 2022 | 828.41 Mn |
| Dec 31, 2021 | 776.63 Mn |
| Sep 30, 2021 | 775.08 Mn |